MXPA01007956A - Polipeptido antimicrobiano/neutralizador de endotoxina. - Google Patents

Polipeptido antimicrobiano/neutralizador de endotoxina.

Info

Publication number
MXPA01007956A
MXPA01007956A MXPA01007956A MXPA01007956A MXPA01007956A MX PA01007956 A MXPA01007956 A MX PA01007956A MX PA01007956 A MXPA01007956 A MX PA01007956A MX PA01007956 A MXPA01007956 A MX PA01007956A MX PA01007956 A MXPA01007956 A MX PA01007956A
Authority
MX
Mexico
Prior art keywords
polypeptide
kda
present
endotoxin
patient
Prior art date
Application number
MXPA01007956A
Other languages
English (en)
Inventor
David M Mann
Original Assignee
Endogen Res Ph Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endogen Res Ph Ab filed Critical Endogen Res Ph Ab
Publication of MXPA01007956A publication Critical patent/MXPA01007956A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un polipeptido huesped-defensa de 6 kDa el cual es generado por la digestion proteolitica de la molecula Iactoferrina El polipeptido huesped-defensa de 6 kDa tiene actividad antimicrobiana y tambien actividad de neutralizacion o neutralizadora de endotoxina. Tambien se describen variantes funcionales de polipeptido huesped-defensa de 6 kDa, las cuales incluyen truncamientos N-terminales y C-terminales del polipeptido de 6kDa y otras modificaciones del polipeptido, tales corno substituciones de aminoacido que conservan o mejoran la actividad. Otro aspecto de la presente invencion se refiere a un metodo terapeutico para trata o prevenir una enfermedad que resulta de infecciones microbianas bacterianas o fungicas en un individuo. Otro aspecto de la presente invencion es el uso del polipeptido LF de 6 kDa y variantes funcionales del mismo para potenciar la accion terapeutica de un farmaco antimicrobiano en un paciente. En otro aspecto, la presente invencion se refiere a un metodo para neutralizar la circulacion de endotoxina en un paciente, administrando el polipeptido de neutralizacion de endotoxina a su variante funcional de la presente invencion al paciente. Tambien, dentro del alcance de la presente invencion, se abarcan metodos para potenciar la actividad de neutralizacion de endoxina y antimicrobiana del polipeptido de la presente invencion. Ademas, tambien se describen metodos para elevar la produccion in vivo del fragmento LF de 6 kDa en un paciente, a traves de proteasas in vivo.
MXPA01007956A 1999-02-05 2000-01-27 Polipeptido antimicrobiano/neutralizador de endotoxina. MXPA01007956A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/245,527 US6399570B1 (en) 1999-02-05 1999-02-05 Antimicrobial/endotoxin neutralizing polypeptide
PCT/IB2000/000271 WO2000049040A2 (en) 1999-02-05 2000-01-27 Antimicrobial/endotoxin neutralizing polypeptide

Publications (1)

Publication Number Publication Date
MXPA01007956A true MXPA01007956A (es) 2004-08-19

Family

ID=22927039

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01007956A MXPA01007956A (es) 1999-02-05 2000-01-27 Polipeptido antimicrobiano/neutralizador de endotoxina.

Country Status (12)

Country Link
US (2) US6399570B1 (es)
EP (1) EP1151009B1 (es)
JP (1) JP2002541066A (es)
CN (1) CN1362969A (es)
AT (1) ATE373679T1 (es)
AU (1) AU758150B2 (es)
CA (1) CA2362153C (es)
DE (1) DE60036456T2 (es)
DK (1) DK1151009T3 (es)
ES (1) ES2293892T3 (es)
MX (1) MXPA01007956A (es)
WO (1) WO2000049040A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US7060677B1 (en) 1999-11-11 2006-06-13 Am-Pharma B.V. Antimicrobial activity of the first cationic cluster of human lactoferrin
CA2484656A1 (en) * 2002-05-10 2003-12-04 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
AU2003270690B2 (en) 2002-09-16 2009-07-30 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004103285A2 (en) 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
EP1635766A4 (en) * 2003-06-06 2009-09-30 Agennix Inc LACTOFERRIN AS ADJUVANS IN CANCER VACCINES
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
KR101317100B1 (ko) 2005-12-30 2013-10-15 에보니크 룀 게엠베하 세포-침투성 펩티드로서 유용한 펩티드
EP2050461A1 (en) 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
EP2060586A1 (en) 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
US20090209486A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions of carbohydrates as dietary supplements
US20090209488A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions for the treatment of exercise induced asthma
US20090209487A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions of carbohydrates as dietary supplements
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
US20090209489A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown Compositions for the treatment of diabetis, system PH disorders, high blood pressure, and a cancer marker system
CN101294188B (zh) * 2008-06-20 2011-06-15 江南大学 乳铁蛋白抗菌肽及其制备方法与它们的用途
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
CN101798337B (zh) * 2010-01-29 2013-04-24 中国人民解放军第三军医大学第一附属医院 内毒素中和肽突变体及其应用
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
JP5763024B2 (ja) * 2012-09-07 2015-08-12 株式会社明治 栄養組成物
WO2014124047A1 (en) 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
CA2972397A1 (en) * 2014-10-08 2016-04-14 Nrl Pharma, Inc. Inhibitor of extracellular trap formation in leukocyte
US10308679B2 (en) * 2014-11-03 2019-06-04 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
AU2017270201A1 (en) * 2016-05-27 2018-11-29 Academia Sinica Modified antimicrobial peptide derived from an arginine-rich domain
CN105999236A (zh) * 2016-07-06 2016-10-12 方雅悯 一种治疗牛乳房炎的药剂及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US6020015A (en) * 1988-09-22 2000-02-01 Gaull; Gerald E. Infant formula compositions and nutrition containing genetically engineered human milk proteins
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5141743A (en) * 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
DE69017921T2 (de) 1990-01-23 1995-10-12 Morinaga Milk Industry Co Ltd Lactoferrinhydrolysat zur Verwendung als tyrosinagehemmendes Mittel.
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
DE4008033A1 (de) 1990-03-14 1991-09-19 Nitsche Dietrich Verwendung von lactoferrin zur bekaempfung der toxischen wirkung des endotoxins
US5240909B1 (en) * 1990-03-14 1998-01-20 Dietrich Nitsche Use of lactoferrin for treatment of toxic effects of endotoxins
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
ATE148631T1 (de) * 1990-11-13 1997-02-15 Santen Pharmaceutical Co Ltd Therapeutische agens bei hornhautverletzungen
JP3110078B2 (ja) 1991-06-21 2000-11-20 森永乳業株式会社 高純度抗菌性ペプチドの大量製造法
DE69220679T2 (de) 1992-01-23 1997-10-23 Morinaga Milk Industry Co Ltd Antibakterielles mittel und behandlung von gegenständen mit diesem
CA2090658A1 (en) * 1992-03-02 1993-09-03 Kunio Ando Formulated medicine for treatment and/or prevention of opportunistic infectious diseases complicated by infection with lentivirus
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
JP3770624B2 (ja) 1993-09-02 2006-04-26 雪印乳業株式会社 ウィルス感染・増殖抑制剤
CA2183459A1 (en) * 1994-02-16 1995-08-24 Jan H. Nuijens Isolation of lactoferrin from milk
NL1000332C1 (nl) 1994-08-31 1996-03-04 Victor Smit Graduele chemische modificatie van biologisch actieve peptiden en eiwitten.
JP3506274B2 (ja) 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
US5531989A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
JPH08165248A (ja) 1994-12-15 1996-06-25 Nobuo Kuriiwa エンドトキシンによる炎症の抑止剤
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
AU5386996A (en) * 1995-04-05 1996-10-23 Picower Institute For Medical Research, The Agents for binding to advanced glycosylation endproducts, an d methods of their use
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
AU723005B2 (en) * 1996-08-14 2000-08-17 Novartis Ag Peptide with inhibitory activity towards plant pathogenic fungi
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof
JP2001519815A (ja) * 1997-04-10 2001-10-23 エイジェニックス・インコーポレイテッド アレルゲン誘発性障害の治療におけるラクトフェリンの使用
FR2762850B1 (fr) * 1997-05-02 2000-02-11 Biocem Lactoferrines recombinantes, leurs procedes de production par les plantes ainsi que leurs utilisations
ATE255130T1 (de) 1997-09-16 2003-12-15 Wolf-Georg Forssmann Bifidogene peptide und deren verwendung
US20020165128A1 (en) * 1998-04-13 2002-11-07 Plaut Andrew G. Compositions and methods for proteolytically inactivating infectious agents using lactoferrin and related molecules
CA2330390C (en) * 1998-04-30 2005-11-08 Morinaga Milk Industry Co., Ltd. Sugar coated tablets
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6719973B1 (en) * 1998-12-24 2004-04-13 National University Of Singapore Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6613741B2 (en) * 1999-10-29 2003-09-02 Ferro Dynamics, Inc. Method for treating aseptic SIRS in humans and other animals
TWI237695B (en) * 1999-12-14 2005-08-11 Joy Biomedical Corp Helicobacter pylori antigens in blood
US20040157277A1 (en) * 2002-03-08 2004-08-12 Clancy Robert Llewellyn Methods for predicting and/or diagnosing the risk of gastric cancer
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US7020715B2 (en) * 2000-08-22 2006-03-28 Adaptec, Inc. Protocol stack for linking storage area networks over an existing LAN, MAN, or WAN
KR100454595B1 (ko) * 2001-11-30 2004-10-28 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 형질전환 대장균
CA2484656A1 (en) * 2002-05-10 2003-12-04 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
AU2003270690B2 (en) * 2002-09-16 2009-07-30 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
CA2530454A1 (en) * 2003-06-24 2005-01-13 Akzo Nobel N.V. Removal of lipopolysaccharides from protein- lipopolysaccharide complex es by nonflammable solvents
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof

Also Published As

Publication number Publication date
CN1362969A (zh) 2002-08-07
DK1151009T3 (da) 2008-01-28
US20030105006A1 (en) 2003-06-05
AU2822600A (en) 2000-09-04
ES2293892T3 (es) 2008-04-01
CA2362153C (en) 2009-11-24
WO2000049040A3 (en) 2000-12-14
DE60036456T2 (de) 2008-06-19
JP2002541066A (ja) 2002-12-03
US7244706B2 (en) 2007-07-17
US6399570B1 (en) 2002-06-04
EP1151009B1 (en) 2007-09-19
ATE373679T1 (de) 2007-10-15
EP1151009A2 (en) 2001-11-07
WO2000049040A2 (en) 2000-08-24
CA2362153A1 (en) 2000-08-24
DE60036456D1 (de) 2007-10-31
AU758150B2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
MXPA01007956A (es) Polipeptido antimicrobiano/neutralizador de endotoxina.
US8461113B2 (en) Elastin digest compositions and methods utilizing same
JOP20210262A1 (ar) تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد
MX2008009493A (es) Peptido novedoso y uso del mismo.
MXPA05011524A (es) Acidos carboxilicos sustituidos.
HK1044477B (zh) 治療糖尿病的藥物
MXPA05010937A (es) Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes.
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
NZ595063A (en) Polypeptides from neisseria meningitidis
TW200630327A (en) Substituted phenylalkanoic acids
EA200600352A1 (ru) Гидролизат казеина, способ его получения и применение
MXPA05011537A (es) Acidos aminocaboxilicos sustituidos.
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
WO2003037932A3 (en) Human coagulation factor vii polypeptides
EP2039367A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
AU2013202269A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
TW200631949A (en) Substituted carboxylic acids
CA2514584A1 (en) Peptide inhibitors of toxins derived from ll-37
US8815812B2 (en) Synthetic arginine substituted peptides and their use
US20110053833A1 (en) Synthetic peptides and their use
JP2020508984A5 (es)
JP6018614B2 (ja) アンギオテンシンｉ転換酵素抑制と血圧低下に用いる短鎖活性ペプチド
MX2022003598A (es) Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas.
WO2004094462A3 (en) Methods of peptide preparation

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees